近年来,大量中国生物技术公司向西方制药巨头密集授权创新药,这一趋势正在改变全球对于创新药的估值。资本市场认为,中国在生物技术领域的崛起虽历经多年,但现在来自中国的力量已无法忽视,发生在生物技术领域的“DeepSeek时刻”已经来临。 创新药格局出现新变化 最新的交易发生在2月6日,复宏汉霖宣布与Reddys Laboratories SA就公司自主开发的在研达雷妥尤单抗生物类似药HLX15(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.